ADA 2026 Standards of Care Section 16 Refines Inpatient Diabetes Management Across Glycemia, Technology, and Perioperative Care
The 2026 ADA hospital standards give endocrinology and obesity pharmacists updated guidance on inpatient CGM and AID continuation, SGLT2 inhibitor use in heart failure, and personalized perioperative management of GLP-1 and dual GIP/GLP-1 receptor agonists.
📅 Journal publication: Jan 1, 2026·Last updated: Oct 19, 2026
ADA Standards of Care in Diabetes 2026American Diabetes Associationinpatient diabeteshyperglycemiahypoglycemiainsulinSGLT2 inhibitorsGLP-1 receptor agonistsCGMDKAperioperativeEndocrinology / Obesity
Background Information
New ADA guidelines for inpatient diabetes management unveiled.
The 2026 ADA Standards of Care update provides new guidelines for managing diabetes in hospitalized patients. Revised inpatient glycemic targets and insulin regimens are included, with a focus on perioperative care and transitions. These guidelines offer actionable insights for pharmacists involved in medication management and transitional care for diabetic patients in hospital settings. New ADA guidelines refine inpatient diabetes management, important for pharmacists in hospital practice.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:American Diabetes Association Professional Practice Committee for Diabetes*
Citation:American Diabetes Association Professional Practice Committee for Diabetes* 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026. Diabetes care. 2026;49(Supplement_1):S339-S355. doi:10.2337/dc26-S016
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.